title: Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.
abstract: The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Andrés-Guerrero
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Lucía
authors.initials: L
authors.lastname: Perucho-González
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Julián
authors.initials: J
authors.lastname: García-Feijoo
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Morales-Fernández
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Saenz-Francés
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: Herrero-Vanrell
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Universitario Miguel Servet, Saragossa, Spain.|Aragon Health Sciences Institute, Saragossa, Spain.
authors.forename: Luis Pablo
authors.initials: LP
authors.lastname: Júlvez
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Universitario Miguel Servet, Saragossa, Spain.|Aragon Health Sciences Institute, Saragossa, Spain.
authors.forename: Vicente Polo
authors.initials: VP
authors.lastname: Llorens
authors.affiliation: Ocular Pathology National Net OFTARED of the Institute of Health Carlos III, Madrid, Spain.|Department of Ophthalmology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain.|Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain.
authors.forename: José María
authors.initials: JM
authors.lastname: Martínez-de-la-Casa
authors.affiliation: 1st and 3rd University Departments of Ophthalmology, AHEPA Hospital, Aristotle University of Thessaloniki, 1 Kyriakidi Street, 546 36, Thessaloniki, Greece. konstas@med.auth.gr.
authors.forename: Anastasios-Georgios
authors.initials: AG
authors.lastname: Konstas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000068258:Bevacizumab / Q000494:pharmacology*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D000069579:Ranibizumab / Q000494:pharmacology*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Aflibercept; Angiogenesis; Bevacizumab; Glaucoma filtration surgery; Neovascular glaucoma; Ranibizumab; VEGF; Wound modulation